Modified ice study: A phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer

Lung Cancer

Volumn 21, Issue 2, 1998, Pages 115-126

  Shevlin, P M ^a   Muers, M F ^b   Peake, M D ^c   Hosker, H S R ^d   Stead, M L ^a   Poulter, K M ^a   Brown, J M ^a  

^a Arthington House   (United Kingdom)

^b Killingbeck Hospital   (United Kingdom)

^c Pontefract General Infirmary   (United Kingdom)

^d AIREDALE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Quality of life; Small cell lung cancer; Toxicity

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DYSPHAGIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; QUALITY OF LIFE;

EID: 0032414054     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00035-X     Document Type: Article

References (27)

1. Connolly CK et al. Carcinoma of bronchus in the Yorkshire Region of England 1974-1990: trends since 1984. Eur Respir J. 10:1997;397-403.
2. Medical Research Council Lung Cancer Working Party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small cell-lung cancer. Respir Med 1989;83:51-8.
3. Rawson NSB, Peto J An overview of prognostic factors in small cell lung cancer. Br J Cancer. 61:1990;597-604.
4. Report of a Working Group to the Standing Medical Advisory Committee, Department of Health (1994). Management of Lung Cancer. Current clinical practices.
5. Thatcher N et al. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. Br J Cancer. 60:1989;98-101.
6. Medical Research Council Lung Cancer Working Party. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small-cell lung cancer (SCLC). (1): Survival and prognostic factors. Br J Cancer 1993;68:1150-6.
7. Medical Research Council Lung Cancer Working Party. Randomised trial of 4-drug versus less intensive 2-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996;73:406-13.
8. Boni C, Cocconi G, Bisagni G et al. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. Cancer. 63:1989;638-642.
9. Medical Research Council, Lung Cancer Working Party. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). (II) Quality of Life. Br J Cancer 1993;68:1157-66.
10. Medical Research Council Lung Cancer Working Party. Controlled trial of 12 versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989;59:584-90.
11. Smith IE et al. Carboplatin, etoposide and ifosfamide as intensive chemotherapy in small cell lung cancer. J Clin Oncol. 8(5):1990;899-905.
12. Thatcher N Ifosfamide/carboplatin/etoposide (ICE) regimen in small cell lung cancer. Lung Cancer (Suppl 1). 9:1993;51-67.
13. Prendiville J et al. Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. Eur J Cancer. 14:1994;2085-2090.
14. Joslin CF, Rider L. Yorkshire Regional Cancer Organisation. Cancer in Yorkshire. Cancer Registry Special Report series. (1) Lung Cancer. Leeds, Yorkshire Regional Cancer Organisation, 1994.
15. Slevin ML et al. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol. 7:1989;1333-1340.
16. Medical Research Council Lung Cancer Working Party. Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer 1991;64:299-306.
17. Heson J Statistical aspects in the design and analysis of phase II clinical trials. Buyse ME, Staquet MJ, Sylvestor RJ Cancer Clinical Trials: Methods and Practice. 1988;239-257 Oxford Medical Publications.
18. Muers MF How much investigation? Thatcher N, Spiro S New Perspectives in Lung Cancer. 1994;77-104 BMJ Publishing Group, London.
19. Handbook for reporting results of cancer treatments. WHO Offset Publication, No 48, Geneva, WHO, 1979.
20. Parmar MKB, Machin D Survival Analysis: A Practical Approach. 1995;21-50 Wiley, England.
21. Calvert AH Dose optimisation of carboplatin in adults. Anticancer Res. 14:1994;2273-2278.
22. Clark PI, Cottier B The activity of 10, 14 and 21-day schedules of single-agent etoposide in previously untreated patients with extensive SCLC. Semin Oncol (Suppl 14). 19:1992;36-39.
23. Medical Research Council Lung Cancer Working Party. Comparison of oral Etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer. A stopped multicentre randomised trial. Lancet 1996;348:563-6.
24. Harper C et al. A randomised study of oral etoposide versus combination chemotherapy in poor prognosis small cell lung cancer. Proc Ann Soc Clin Oncol (2019 abstract). 15:1996;27.
25. Miller AA et al. Schedule dependency of 21 day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage SCLC: a randomised phase II study of the cancer and leukaemia group B. J Clin Oncol. 13:1995;1871-1879.
26. Kaasa S, Mastekaasa A, Ness S Quality of life of lung cancer patients in a randomised clinical trial evaluated by a psychosocial well-being questionnaire. Factor Oncol. 27:1988;829-835.
27. Hatton MQF et al. On behalf on the West of Scotland Lung Cancer Group. Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? Eur J Cancer. 31(6):1995;1022-1023.